Engineers Gate Manager’s Definium Therapeutics DFTX Stock Holding History

Engineers Gate Manager’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$481K	Sell	10,233 -19,534	-66%	-$483K	0.01%	1542
2026 Q1	$563K	Buy	+29,767	New	+$505K	0.01%	1349
2023 Q1	–	Sell	-10,076	Closed	-$22.2K	–	1866
2022 Q4	$22.2K	Buy	+10,076	New	+$28K	﹤0.01%	1598
2021 Q3	–	Sell	-1,143	Closed	-$59K	–	1842
2021 Q2	$59K	Buy	+1,143	New	+$60K	﹤0.01%	1540

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Engineers Gate Manager's DFTX Position: Q2 2026 in Review

Engineers Gate Manager reduced its Definium Therapeutics (DFTX) stake by 66% in Q2 2026, selling an estimated $483K and leaving 10,233 shares worth $481K. The position accounts for 0.01% of the portfolio, ranked #1542.

Engineers Gate Manager first reported a position in DFTX in Q2 2021 and has held it in 4 quarters since. The position peaked at $563K in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Engineers Gate Manager held 10,233 shares of Definium Therapeutics worth $481K as of Q2 2026.
Engineers Gate Manager sold 19,534 Definium Therapeutics shares in Q2 2026, an estimated $483K.
Definium Therapeutics made up 0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1542 holding.
Engineers Gate Manager first reported a position in Definium Therapeutics in Q2 2021 and has held it in 4 quarters since.
Engineers Gate Manager's Definium Therapeutics position peaked at $563K in Q1 2026.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.